Exicure, Inc. (XCUR)
1.25
+0.02
(+1.63%)
USD |
NASDAQ |
Sep 04, 16:00
1.23
-0.02
(-1.60%)
After-Hours: 20:00
Exicure Research and Development Expense (Quarterly) : 0.174M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.174M |
| March 31, 2026 | 0.312M |
| December 31, 2025 | 0.655M |
| September 30, 2025 | 0.888M |
| June 30, 2025 | 0.935M |
| March 31, 2025 | 0.808M |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.992M |
| December 31, 2022 | 0.615M |
| September 30, 2022 | 4.341M |
| June 30, 2022 | 6.286M |
| March 31, 2022 | 6.838M |
| Date | Value |
|---|---|
| December 31, 2021 | 10.33M |
| September 30, 2021 | 16.01M |
| June 30, 2021 | 10.40M |
| March 31, 2021 | 9.837M |
| December 31, 2020 | 9.437M |
| September 30, 2020 | 8.98M |
| June 30, 2020 | 6.821M |
| March 31, 2020 | 5.927M |
| December 31, 2019 | 8.267M |
| September 30, 2019 | 4.245M |
| June 30, 2019 | 3.433M |
| March 31, 2019 | 3.395M |
| December 31, 2018 | 3.008M |
| September 30, 2018 | 4.001M |
| June 30, 2018 | 3.835M |
| March 31, 2018 | 3.275M |
| December 31, 2017 | 3.17M |
| September 30, 2017 | 3.121M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | 12.85M |
| Century Therapeutics, Inc. | 16.98M |
| Absci Corp. | 22.62M |
| Celularity, Inc. | 1.92M |
| Cardio Diagnostics Holdings, Inc. | 0.1629M |